Actinium Pharmaceuticals, Inc.
シンボルマーク: ATNM
AMEX
8.75
USD今日の市場価格
-5.2530
PER(株価収益率
0.0000
PEGレシオ
260.61M
MRK キャップ
- 0.00%
DIV利回り
Actinium Pharmaceuticals, Inc. (ATNM) 財務諸表
貸借対照表
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 334.99 | 76.7 | 108.9 | 77.8 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 9.78 | 1.6 | 2 | 1.9 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 344.77 | 78.3 | 110.9 | 79.7 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 11.78 | 2.9 | 2.9 | 0.6 | ||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.long-term-investments | 1.25 | 0.3 | 0.3 | 0 | ||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | -0.6 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 13.02 | 3.2 | 3.3 | 0.6 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 357.79 | 81.4 | 114.2 | 80.4 | ||||||||||||||||||
balance-sheet.row.account-payables | 32.25 | 8 | 10.1 | 5.5 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 2.13 | 0.5 | 0.5 | 0.3 | ||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 6.51 | 1.6 | 2.1 | 0 | ||||||||||||||||||
Deferred Revenue Non Current | 140 | 35 | 35 | 0 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -106.57 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | -104.46 | -35 | -35 | 0 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 146.51 | 36.6 | 37.1 | 0 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 7.55 | 1.6 | 2.6 | 0.3 | ||||||||||||||||||
balance-sheet.row.total-liab | 180.9 | 45.1 | 47.7 | 6.8 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 0.11 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.retained-earnings | -1327.08 | -337.6 | -288.8 | -255.7 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1503.86 | 373.9 | 355.2 | 329.3 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 176.9 | 36.4 | 66.5 | 73.5 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 357.79 | 81.4 | 114.2 | 80.4 | ||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-equity | 176.9 | 36.4 | 66.5 | 73.5 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 357.79 | - | - | - | ||||||||||||||||||
Total Investments | 1.25 | 0.3 | 0.3 | 0 | ||||||||||||||||||
balance-sheet.row.total-debt | 8.64 | 2.1 | 2.6 | 0.3 | ||||||||||||||||||
balance-sheet.row.net-debt | -326.35 | -74.6 | -106.3 | -77.5 |
キャッシュフロー計算書
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -46.45 | -48.8 | -33 | -24.8 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0.82 | 0.8 | 0.7 | 0.5 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | -3.47 | 2.2 | 0.4 | -1.5 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 4.23 | 3.8 | 2.8 | 1.7 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 1.77 | -3.1 | 38.2 | 1.7 | ||||||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.account-payables | 0.15 | -2.2 | 4.6 | 1.2 | ||||||||||||||||||
cash-flows.row.other-working-capital | 1.61 | -1 | 33.6 | 0.5 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 5.72 | -2.2 | -0.4 | 1.5 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -39.63 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.09 | -0.2 | -0.4 | -0.1 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -0.09 | -0.2 | -0.4 | -0.1 | ||||||||||||||||||
cash-flows.row.debt-repayment | -0.01 | 0 | 0 | -0.1 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 28.61 | 14.9 | 23.2 | 35.3 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.other-financing-activites | 19.08 | 0.3 | 23.1 | 0 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 28.87 | 14.9 | 23.1 | 35.2 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | -10.86 | -32.6 | 31.4 | 14.2 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 335.61 | 76.7 | 109.6 | 78.2 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 346.46 | 109.3 | 78.2 | 64 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | -39.63 | -47.3 | 8.6 | -20.9 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -0.09 | -0.2 | -0.4 | -0.1 | ||||||||||||||||||
cash-flows.row.free-cash-flow | -39.72 | -47.5 | 8.3 | -21 |
損益計算書の行
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0.08 | 0.1 | 1 | 1.1 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0.82 | 0.8 | 0.7 | 0.5 | ||||||||||||||||||
income-statement-row.row.gross-profit | -0.74 | -0.7 | 0.3 | 0.6 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 37.04 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 12.56 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.22 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 49.6 | 51.2 | 35.1 | 26.1 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 50.01 | 52 | 35.1 | 26.1 | ||||||||||||||||||
income-statement-row.row.interest-income | 3.48 | 3.1 | 1.1 | 0.2 | ||||||||||||||||||
income-statement-row.row.interest-expense | 0.55 | 0 | -1.1 | 0 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.22 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 3.48 | 3.1 | 1.1 | 0.2 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | 3.48 | 3.1 | 1.1 | 0.2 | ||||||||||||||||||
income-statement-row.row.interest-expense | 0.55 | 0 | -1.1 | 0 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0.82 | 0.8 | 0.7 | 0.5 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | -49.11 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | -49.93 | -51.9 | -34.1 | -25 | ||||||||||||||||||
income-statement-row.row.income-before-tax | -46.45 | -48.8 | -33 | -24.8 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | 0.55 | 0 | -1.1 | -0.2 | ||||||||||||||||||
income-statement-row.row.net-income | -46.45 | -48.8 | -31.9 | -24.6 |
よくある質問
Actinium Pharmaceuticals, Inc.ATNM 総資産とは何ですか?
Actinium Pharmaceuticals, Inc. (ATNM) 総資産は 81445000.000.
企業の年間売上高とは?
年間収益は 81000.000である.
企業の利益率は?
利益率は -9.173 である.
企業のフリーキャッシュフローとは?
フリーキャッシュフローは -1.424.
企業の純利益率は?
純利益率は -573.469 である.
企業の総収入は?
総収入は -616.457 である.
Actinium Pharmaceuticals, Inc. (ATNM) 純利益(純利益)とは何ですか?
純利益(純利益)は -48818000.000.
負債総額は?
負債合計は 2113000.000 である.
営業費用はいくらですか?
営業費用は 51211000.000 である.
会社の現金はいくらですか?
企業の現金は 84057000.000 である.